2Skates SJ, Xu FJ. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers[J].Cancer,1995,76(10 Suppl):2004-2010.
3Davelaar EM, Schutter EM, Von S, et al. Clinical and technical evaluation of the ACS: OV serum assay and comparison with three other CA125-detecing assays[J].Ann Clin Biochem,2003,40:663.
4Ardekani AM, Liotta LA, Petricoin EF, et al. Clinical potential of proteomics in the diagnosis of ovarian cancer[J].Expert Rev Mol Diagn,2002,2(4):312-320.
5Hogdall EV, Hogdall CK, Tingulstad S, et al. Predictive values of serum tumor markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass[J].Int J Cancer,2000,89(6):519-523.
6Jeyarajah AR, Ind TE, Macdonald N, et al. Increased mortality in postmenopausal women with serum CA125 elevation[J].Gynecol Oncol,1999,73(2):242-246.
7Engelen MJ, de Bruijn HW, Hollema H, et al. Serum CA125, carcinoembryonic antigen, and CA19-9 as tumor markers in borderline tumors[J].Gynecol Oncol,2000,78(1):16-20.
8Gerado I, Sonia R, Andrea L, et al. Ultrasound examination, and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors[J].Gynecol Oncol,2001,81:63-66.
9Nyvang GB, Mogensen O, Bichel P, et al. Combined prognostic importance of CA125, histopathologic grade and DNA-index in advanced ovarian cancer[J].Eur J Gynecol Oncol,2000,21(6):569.
1[1]Woolas RP,Xu FJ,Jacobs IJ,et al.Elevation of multiple serum markers in patients with stage I ovarian cancer[J].J Natl Cancer Inst，1993，85(21):1748-1751．
2[2]Onetto M,Bruzzone M,Conte PF,et al.Evaluation of the ovarian cancer antigen,Ca-125, as a tumor marker[J].Oncology，1989，46(2):117-122 ．
3[3]Woolas R,Jacobs IJ,Xu FJ,et al.Serum levels of CA125,M-CSF and OVX1 in stage I and preclinical ovarian cancer[J].Proc AM Clin Oncol，1993，12:110．
4[4]Berek JS,Bast RC.Ovarian cancer screening.The use of serial complementary tumor markers to improve sensitivity and specificity for early detection[J].Cancer，1995，76(Suppl 10):2092-2096．
5[5]Crombach G,Zippel HH,Wurz H.Clinical significance of cancer antigen 125(CA 125) in ovarian cancer[J].Cancer Detect Prev，1985，8(1-2):135-139．
6[6]Halila H,Lehtovirta P,Stenman UH,et al.CA125 in the follow-up of patients with ovarian cancer[J].Acta Obstet Gynecol Scand，1988，67(1):53-58．
7[7]Venesmaa P,Lehtovirta P,Stenman UH,et al.Tumor-associated trypsin inhibitor(TATI):comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer[J].Br J Cancer,1994,70(6):1188-1190．
8[8]Nagele F,Petru E,Medl M,et al.Preoperative CA 125:an independent prognostic factor in patients with stage Ⅰ epithelial ovarian cancer[J].Obstet Gynecol,1995,86(2):259-264．
9[1]Robert C,Bast JR,Thomas L,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer [J ]. New Engl J Med, 1983, 309(15) :883.
10[2]Alvarez RD, To A, Boots LR, et al. CA125 as a serum maker for poor prognosis in ovarianmalignancies[J]. Gynecol Oncol, 1987,26(3) :284.
